Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

sections

Are we getting the most out of our patients?

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Yes, you read it right – are we getting the most out of our patients, or more accurately are patients getting the most out of other patients?


Let me explain myself!


As a pharmacy student, we are regularly reminded about those drugs in the BNF with ‘black triangle’ status.  As you are all probably aware, those are the drugs that have been newly licensed and are in phase 4 clinical trials.  It may also be that it is an older drug that has just been licensed for a new indication.  This alerts us to the fact that greater surveillance is needed and that both healthcare professionals and patients need to be alert for any possible adverse events.  This is all well and good but is it ok for us to step down our surveillance after the black triangle status has been removed?


We just need to think back over the last year for new clinical information that has emerged surrounding the use of older drugs.  The new interaction between calcium channel blockers and high doses of statins and the newly published information regarding cardiac side effects of domperidone being two prime examples.


With polypharmacy seeming to increase every year, patients are taking new combinations of medicines with untested results.  A lot of the ‘interactions’ that computer programmes alert us to are merely theoretical interactions but how much notice do we pay to these and what impact does that have on the patient?  A lot of the time, we just don’t know. 


The introduction of MURs and NMS schemes have helped to give patients the opportunity to talk about their medicines and any problems they are having with them, but are we targeting enough patients?   Or the right types of patients?  Is there a better way of obtaining such information from our patients in order to help other patients?  Maybe there are; information slips under each item on a repeat prescription form, boxes for patients to put comments about their medicines (somewhat like a comments box), a dedicated telephone line to receive specific problems with any medication.  I appreciate the presence of the yellow card scheme for reporting such events, but are patients and pharmacists aware enough to be able to utilise this to its best?  I’m not totally convinced.  Are pharmacists holding back on reporting seemingly minor side effects?  Possibly.  There may well be a better way to obtain information from our patients but where does it start?

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

From: Tomorrow's pharmacist blog

Students and preregistration trainees voice their opinions here

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.